Boston Scientific Q3 Earnings Comes Inline With Wall Street Expectations

  • Boston Scientific Corporation BSX generated net sales of $2.93 billion in Q3 of 2021, almost in line with the Wall Street estimate of $2.97 billion.
  • Sales increased 10.3% Y/Y on a reported basis and 10.6% on an organic basis, lower than the Company's guidance of 12% - 14%.
  • The Company achieved adjusted EPS of $0.41, slightly ahead of the consensus of $0.40, in line with guidance of $0.39 - $0.41.
  • Revenues from MedSurg increased 11.2% to $917 million (9.4% organic), Rhythm and Neuro increased 8.2% to $819 million (1.5% organic), and Cardiovascular segment generated $1.19 billion, +19.4% (18.5% organic).
  • The gross margin expanded from 67.3% to 69.3%. It posted an operating income of $387 million, compared to an operating loss of $(205) million a year ago.
  • FY21 Guidance: Boston Scientific sees adjusted EPS of $1.60 - $1.62 (consensus of $1.61), compared to the earlier outlook of $1.58-$1.62.
  • It estimates revenue growth of approximately 19% - 20% on a reported basis and 18% - 19% organically, compared to earlier guidance of 21% - 22% and 19% - 20%, respectively.
  • For Q4, BSX expects an adjusted EPS of $0.43 - $0.45.
  • Price Action: BSX shares are down 0.27% at $44.20 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!